Jazz Pharmaceuticals (NASDAQ:JAZZ) Reaches New 52-Week High – Should You Buy?

Posted by Francis Steltz on Aug 27th, 2026

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $266.25 and last traded at $265.7180, with a volume of 416987 shares changing hands. The stock had previously closed at $254.47.

More Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

Positive Sentiment: The FDA approved two Ziihera (zanidatamab-hrii) combination regimens as first-line treatments for adults with unresectable, locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma. The approval broadens Ziihera’s addressable market and could accelerate the drug’s path toward blockbuster sales. FDA approves Ziihera regimens
Positive Sentiment: Truist raised its JAZZ price target to $281 from $264 and maintained a Buy rating, while Needham increased its target to $310 from $292 and also reiterated Buy. The revisions reflect increased confidence in Ziihera’s commercial opportunity following the FDA decision. Analyst price target increases
Positive Sentiment: Zacks Research raised its forecast for second-quarter 2028 EPS to $6.09 from $6.04 and projects fiscal 2028 EPS of $22.74, modestly above the current-year consensus estimate of $21.66.
Neutral Sentiment: Jazz priced an upsized $1.1 billion offering of 1.875% exchangeable senior notes due 2032, alongside planned ordinary-share repurchases. The low coupon and buybacks may support capital returns, but the financing increases leverage and could create future share dilution if the notes are exchanged. Jazz prices exchangeable notes
Negative Sentiment: Zacks lowered multiple forward EPS estimates, including fiscal 2026 to $20.77 from $21.72 and fiscal 2027 to $20.02 from $22.26. Estimates also declined for several quarters through 2028, signaling somewhat softer projected earnings momentum despite the favorable Ziihera outlook.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Royal Bank Of Canada reiterated an “outperform” rating and issued a $277.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday. Bank of America upped their price target on shares of Jazz Pharmaceuticals from $281.00 to $307.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th. JPMorgan Chase & Co. raised their price target on shares of Jazz Pharmaceuticals from $265.00 to $276.00 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. Stifel Nicolaus set a $275.00 price objective on shares of Jazz Pharmaceuticals in a research note on Tuesday, August 4th. Finally, Deutsche Bank Aktiengesellschaft upped their target price on Jazz Pharmaceuticals from $287.00 to $300.00 and gave the company a “buy” rating in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $279.00.

Read Our Latest Research Report on JAZZ

Jazz Pharmaceuticals Price Performance

The company has a quick ratio of 1.58, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. The stock’s 50 day moving average price is $246.38 and its two-hundred day moving average price is $217.52. The stock has a market cap of $16.18 billion, a price-to-earnings ratio of 17.19, a price-to-earnings-growth ratio of 0.23 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.18 by ($0.47). The business had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.11 billion. Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. Jazz Pharmaceuticals’s revenue for the quarter was up 15.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($8.25) earnings per share. Equities research analysts forecast that Jazz Pharmaceuticals PLC will post 21.66 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $252.98, for a total transaction of $1,517,880.00. Following the completion of the transaction, the director directly owned 360,682 shares in the company, valued at approximately $91,245,332.36. This trade represents a 1.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the company’s stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total value of $278,196.00. Following the completion of the sale, the executive vice president owned 51,549 shares in the company, valued at approximately $11,950,604.67. This represents a 2.27% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 14,357 shares of company stock valued at $3,505,642 over the last ninety days. Company insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. California State Teachers Retirement System grew its holdings in Jazz Pharmaceuticals by 24,585.6% in the second quarter. California State Teachers Retirement System now owns 15,714,136 shares of the specialty pharmaceutical company’s stock valued at $3,786,635,000 after purchasing an additional 15,650,479 shares during the period. Capital World Investors grew its stake in Jazz Pharmaceuticals by 4.4% in the 4th quarter. Capital World Investors now owns 2,666,602 shares of the specialty pharmaceutical company’s stock valued at $453,322,000 after acquiring an additional 111,735 shares during the period. Ameriprise Financial Inc. increased its holdings in Jazz Pharmaceuticals by 11.4% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock worth $198,159,000 after acquiring an additional 191,637 shares in the last quarter. Franklin Resources Inc. raised its position in Jazz Pharmaceuticals by 164.0% during the fourth quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock worth $309,215,000 after acquiring an additional 1,129,995 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in Jazz Pharmaceuticals by 44.5% during the first quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock valued at $317,485,000 after purchasing an additional 517,514 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

(Get Free Report)

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.